Latest product



BioGaia Pharax® Kids

Support a faster recovery from Upper Respiratory Tract Infections (URTI)

- Clinically proven to reduce days with fever, and sore throat[18]
- From 6 months
- Strain: *L. reuteri* DSM 17938 and *L. reuteri* ATCC PTA 5289
- Product: oil suspension with neutral taste
- Daily dose: 5 drops/twice per day for 10 days

Probiotics throughout childhood



About BioGaia

BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years and developed ground-breaking and clinically proven probiotic products focusing on different health areas. With a network of over 50 research institutes around the globe, BioGaia is committed to the science behind our products.

References

1. According to the number of publications on https://pubmed.ncbi.nlm.nih.gov/ April 2024
2. Szajewska H et al. Probiotics for the Management of Pediatric Gastro-intestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr. 2023 Feb 1;76(2):232-247. doi:10.1097/MPG.0000000000003633. Epub 2022 Oct 11.
3. Szajewska H et al. *Lactobacillus reuteri* DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013 Feb;162(2):257-62. doi: 10.1016/j.jpeds.2012.08.004.
4. Indrio F et al. Management of the Most Common Functional Gastrointestinal Disorders in Infancy: The Middle East Expert Consensus.Pediatr Gastroenterol Hepatol Nutr. 2021 Jul;24(4):325-336. doi: 10.5223/pghn.2021.24.4.325.
5. Hojsak I et al. European guidance on paediatric use of probiotics states that benefits are limited to several conditions and urges caution with specific vulnerable groups. (Review.) 2018 Acta Paediatr. 107:927-937.
6. Guarner F et al. World Gastroenterology Organisation Global Guideline: Probiotics and prebiotics. 2023.
7. Cameron D et al. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. World J Gastroenterol. 2017 Dec 7;23(45):7952-7964. doi: 10.3748/wjg.v23.i45.7952.
8. Cruchet S et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr Drugs. 2015 Jun;17(3):199-216. doi: 10.1007/s40272-015-0124-6.
9. Patro-Gołąb B, Szajewska H. Systematic Review with Meta-Analysis: *Lactobacillus reuteri* DSM 17938 for Treating Acute Gastroenteritis in Children.
10. Guarino A et al. Universal Recommendations for the Management of Acute Diarrhea in Nonmalnourished Children. J Pediatr Gastroenterol Nutr. 2018 Nov;67(5):586-593. doi: 10.1097/MPG.0000000000002053.
11. Iramain R et al. [Consensus guideline on acute gastroenteritis in the emergency department. Emergency Medicine Committee of SLACIP (Latin American Society of Pediatric Intensive Care)]. 2017 Pediatr a (Asunci n). 44:249-258. doi: 10.18004/ped.2017.diciembre.249-258 (abstract in English).
12. Lo Vecchio A et al. An international consensus report on a new algorithm for the management of infant diarrhoea. Acta Paediatr. 2016;105:e384-389.
13. Trivić I et al. Use of probiotics in the treatment of functional abdominal pain in children-systematic review and meta-analysis. Eur J Pediatr. 2021 Feb;180(2):339-351. doi: 10.1007/s00431-020-03809-y.
14. Weizman Z et al. *Lactobacillus reuteri* DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. J Pediatr. 2016 Jul;174:160-164.e1. doi: 10.1016/j.jpeds.2016.04.003.
15. Romano C et al. *Lactobacillus reuteri* in children with functional abdominal pain (FAP). J Paediatr Child Health. 2014 Oct;50(10):E68-71. doi: 10.1111/j.1440-1754.2010.01797.x
16. Weizman Z et al. *Lactobacillus reuteri* DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. J Pediatr. 2016 Jul;174:160-164.e1. doi: 10.1016/j.jpeds.2016.04.003.
17. Gutiérrez-Castrellón P et al. Diarrhea in preschool children and *Lactobacillus reuteri*: a randomized controlled trial. Pediatrics 2014;133:4 e904-e909.
18. Maya-Barrios A, et al. *Limosilactobacillus reuteri* ATCC PTA 5289 and DSM 17938 as adjuvants to improve evolution of pharyngitis/tonsillitis in children: randomised controlled trial. Benef Microbes. 2021 Apr 12;12(2):137-145. doi: 10.3920/BM2020.0171

BioGaia®
Supporting your invisible heroes

BioGaia AB, Kungsbroplan 3, Box 3242
103 64 Stockholm, Sweden
+46 8 555 293 00, biogaia.com

May 2024

This communication is only intended for healthcare professionals, i.e. not intended for consumers.



L. reuteri, one of the world's most researched probiotic strains[1]

BioGaia's products contain unique and patented strains of the lactic acid bacteria *Limosilactobacillus reuteri*. The products with *L. reuteri* are among the most scientifically well-documented probiotics in the world. Health benefits and efficacy have been shown in numerous clinical studies. Each product from BioGaia contains unique *L. reuteri* strains that provide their own distinct health benefits.

The efficacy and safety of BioGaia's different strains of *L. reuteri* have been shown in:

266 clinical trials

22 634 individuals

57 studies in **7,517** subjects	**28** studies in **3,414** subjects	**44** studies in **4,585** subjects	**137** studies in **7,118** subjects
Infants (0–12 months)	**Toddlers** (13–36 months)	**Children** (4–18 years)	**Adults** (>18 years)

December 2023

BioGaia probiotic products for infants and children

CLINICALLY PROVEN



20 years of colic relief

BioGaia Protectis® drops

The most researched probiotic in infant colic[2]

- Clinically proven to reduce crying and fussing in colicky babies[3]
- Recommended by 6 international clinical guidelines[2, 4-9]
- Safe to use from birth
- Strain: *L. reuteri* DSM 17938
- Product: oil suspension with neutral taste
- Daily dose: 5 drops



BioGaia Protectis® tablets

Relieve functional abdominal pain disorders (FAPD)

- The only probiotic with proven effect in FAPD[13]
- Proven to reduce number of pain episodes and pain intensity[14-15]
- Recommended by 2 international clinical guidelines[2,6]
- From 3 years
- Strain: *L. reuteri* DSM 17938
- Product: chewable tablets with strawberry or lemon flavor
- Daily dose: 1-2 tablets



BioGaia Protectis® powder sachets

Provide fast recovery from acute gastroenteritis (AGE)

- Clinically proven to effectively manage AGE[9]
- Offer rapid relief from diarrheal symptoms within 48 hours[9]
- Recommended by 7 international clinical guidelines[2, 6-8, 10-12]
- For all ages
- Strain: *L. reuteri* DSM 17938
- Product: clean label powder with neutral taste
- Daily dose: 1 to 2 sachets

10 µg vitamin D



BioGaia Protectis® drops and BioGaia Protectis® tablets with vitamin D

Support infants and children's immune system

- All the benefits of BioGaia Protectis drops and tablets with the added benefits of 10 µg vitamin D
- Clinically proven to prevent infections in children[16-17]
- Strain: *L. reuteri* DSM 17938
- Product: oil suspension with neutral taste or chewable tablets with orange flavor
- Daily dose: 5 drops or 1 tablet

5 = = = $1x10^8$ CFU*

*CFU = colony forming units